Literature DB >> 15879444

Fungal infections as a complication of therapy for sarcoidosis.

R P Baughman1, E E Lower.   

Abstract

BACKGROUND: Treatment of symptomatic sarcoidosis usually includes systemic immunosuppressive agents. These agents may render the patient more susceptible to opportunistic infections. In addition, the fungal infection may be difficult to distinguish from the underlying sarcoidosis. AIM: To examine the presentation and management of invasive fungal infections in sarcoidosis patients.
DESIGN: Retrospective record review.
METHODS: We reviewed the notes of all sarcoidosis patients (n = 753) seen at our clinic over an 18-month period.
RESULTS: Seven patients (0.9%) with previously diagnosed sarcoidosis developed fungal infections: two each with Histoplasma capsulatum and Blastomyces dermatitidis and three others with Cryptococcus neoformans. No cases of invasive aspergillus or tuberculosis were identified. The diagnosis of fungal infection was made by bronchoscopy (four cases), open-lung biopsy (one case), bone-marrow aspirate (one case), and spinal fluid examination (one case). All patients were receiving corticosteroids at the time of worsening chest X-ray or clinical status. Four patients were also receiving methotrexate prior to infection. No patient with systemic fungal infection was receiving either infliximab or cyclophosphamide. All patients responded to anti-fungal therapy and a reduction in immunosuppression. DISCUSSION: Fungal infections occur rarely in treated patients with sarcoidosis. Deterioration of chest X-ray, especially a localized infiltrate, warrants investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879444     DOI: 10.1093/qjmed/hci073

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  20 in total

Review 1.  Disease Burden and Variability in Sarcoidosis.

Authors:  Alicia K Gerke; Marc A Judson; Yvette C Cozier; Daniel A Culver; Laura L Koth
Journal:  Ann Am Thorac Soc       Date:  2017-12

Review 2.  Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature.

Authors:  Tahuanty A Pena; Ayman O Soubani; Lobelia Samavati
Journal:  Lung       Date:  2011-02-13       Impact factor: 2.584

Review 3.  Morbidity and mortality in sarcoidosis.

Authors:  Alicia K Gerke
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

4.  Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.

Authors:  Nadera J Sweiss; Imre Noth; Mehdi Mirsaeidi; Wei Zhang; Edward T Naureckas; D Kyle Hogarth; Mary Strek; Philip Caligiuri; Roberto F Machado; Timothy B Niewold; Joe G N Garcia; Aileen L Pangan; Robert P Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2014-04-18       Impact factor: 0.670

5.  A sarcoidosis patient with hand involvement and large pulmonary lymph nodes: results of 1-year treatment with methotrexate.

Authors:  Ebru Alemdaroğlu; Arzu Ertürk; Ayşe Gürler Eroğlu
Journal:  Clin Rheumatol       Date:  2010-06-26       Impact factor: 2.980

6.  Sarcoidosis as risk factor for cryptococcal meningitis in an apparently immunocompetent patient.

Authors:  Iacopo Cancelli; Giovanni Merlino; Anna Serafini; Mariarosaria Valente; Gian Luigi Gigli
Journal:  Neurol Sci       Date:  2008-04-01       Impact factor: 3.307

7.  Fever, splenomegaly and lymphopenia in sarcoidosis. Visceral leishmaniasis.

Authors:  Claudia Ravaglia; Carlo Gurioli; Gian Luca Casoni; Silvia Asioli; Venerino Poletti
Journal:  Thorax       Date:  2012-06-02       Impact factor: 9.139

8.  State-Level Health Disparity Is Associated with Sarcoidosis Mortality.

Authors:  Yu-Che Lee; Ko-Yun Chang; Mehdi Mirsaeidi
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

9.  Sarcoidosis and Histoplasmosis: Is One a Consequence of the Other? A Case Report and Review of the Literature.

Authors:  Anupam Bansal; Rupali Drewek
Journal:  Case Rep Rheumatol       Date:  2015-08-06

Review 10.  Cryptococcal meningitis complicating sarcoidosis.

Authors:  Sonja E Leonhard; Daan Fritz; Diederik van de Beek; Matthijs C Brouwer
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.